From GlobeNewswire: 2025-06-21 18:00:00

BioAge Labs presented new data showing that treatment with an apelin receptor agonist improved glycemic control and had cardioprotective effects, especially when combined with incretin therapy. The data supports the development of next-generation APJ agonists for conditions like obesity and heart failure with preserved ejection fraction. The company is advancing multiple APJ agonist approaches, including oral small-molecule and injectable formulations, with an IND filing planned for 2026. Clinical studies demonstrated that APJ agonist treatment had potential as monotherapy in diabetic obesity and HFpEF, with additional benefits seen when combined with incretin therapies. BioAge faces risks and uncertainties in developing and commercializing product candidates. Results of preclinical and clinical trials may not be replicated, and regulatory approval could be delayed. Adverse safety events and failure to protect intellectual property are concerns. Dependence on collaborators and supply chain disruptions pose additional risks. Legal and regulatory compliance, access to capital, and attracting key personnel are also challenges. BioAge’s Quarterly Report on Form 10-Q highlights these risks. The company will update forward-looking statements as needed. Contacts for media, investor relations, and partnerships are available on their website.



Read more at GlobeNewswire: BioAge Labs to Present Preclinical Data on APJ Agonism for